Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1161/STROKEAHA.114.006573. Epub 2015 Jan 22.
Collaborators, Affiliations
- PMID: 25613308
- DOI: 10.1161/STROKEAHA.114.006573
Randomized Controlled Trial
Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial
Richard I Lindley et al. Stroke. 2015 Mar.
Erratum in
- Correction.
[No authors listed] [No authors listed] Stroke. 2015 Mar;46(3):e73. doi: 10.1161/STR.0000000000000061. Stroke. 2015. PMID: 25713302 No abstract available.
Abstract
Background and purpose: Our aim was to identify whether particular subgroups of patients had an unacceptably high risk of symptomatic intracranial hemorrhage or low chance of benefit when treated with alteplase (recombinant tissue-type plasminogen activator).
Methods: Third International Stroke Trial was an international randomized trial of the intravenous (IV) recombinant plasminogen activator alteplase (0.9 mg/kg) versus control in 3035 (1515 versus 1520) patients. We analyzed the effect of recombinant tissue-type plasminogen activator on 6-month functional outcome, early death, and symptomatic intracranial hemorrhage (both ≤7 days). We tested for any differences in treatment effect between subgroups by a test of interaction. Our 13 protocol prespecified subgroups were time to randomization, age, sex, stroke subtype, atrial fibrillation, early ischemic change (clinician and expert panel), prior antiplatelet use, stroke severity, diastolic and systolic blood pressure at randomization, center's thrombolysis experience, and trial phase. Analyses were adjusted for key baseline prognostic factors.
Results: There were no significant interactions in the subgroups analyzed that were consistent across all 3 outcomes. Treatment with recombinant tissue-type plasminogen activator increased the odds of symptomatic intracranial hemorrhage by a greater amount in patients taking prior antiplatelets than those who were not (P=0.019 for test of interaction), but had no clear detrimental effect on functional outcome at 6 months in this group (P=0.781 for test of interaction).
Conclusions: Among the types of patient in the Third International Stroke Trial, this secondary analysis did not identify any subgroups for whom treatment should be avoided. Given the limitations of the analysis, we found no clear evidence to avoid treatment in patients with prior ischemic stroke, diabetes mellitus, or hypertension.
Clinical trial registration url: http://www.controlled-trials.com. Unique identifier: ISRCTN25765518. http://www.controlled-trials.com/ISRCTN25765518.
Keywords: alteplase; intracranial hemorrhages; stroke; thrombolytic therapy; treatment outcome.
© 2015 American Heart Association, Inc.
Similar articles
- Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
Carr SJ, Wang X, Olavarria VV, Lavados PM, Rodriguez JA, Kim JS, Lee TH, Lindley RI, Pontes-Neto OM, Ricci S, Sato S, Sharma VK, Woodward M, Chalmers J, Anderson CS, Robinson TG; ENCHANTED Investigators. Carr SJ, et al. Stroke. 2017 Sep;48(9):2605-2609. doi: 10.1161/STROKEAHA.117.017808. Epub 2017 Jul 24. Stroke. 2017. PMID: 28739832 - Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
Robinson TG, Wang X, Arima H, Bath PM, Billot L, Broderick JP, Demchuk AM, Donnan GA, Kim JS, Lavados PM, Lee TH, Lindley RI, Martins SCO, Olavarria VV, Pandian JD, Parsons MW, Pontes-Neto OM, Ricci S, Sato S, Sharma VK, Nguyen TH, Wang JG, Woodward M, Chalmers J, Anderson CS; ENCHANTED Investigators. Robinson TG, et al. Stroke. 2017 Jul;48(7):1877-1883. doi: 10.1161/STROKEAHA.116.016274. Epub 2017 Jun 15. Stroke. 2017. PMID: 28619989 Clinical Trial. - Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J, Sandercock P; IST-3 Collaborative Group. Whiteley WN, et al. Stroke. 2014 Apr;45(4):1000-6. doi: 10.1161/STROKEAHA.113.004362. Epub 2014 Mar 6. Stroke. 2014. PMID: 24603072 Free PMC article. Clinical Trial. - Thrombolysis for acute ischaemic stroke.
Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Wardlaw JM, et al. Cochrane Database Syst Rev. 2003;(3):CD000213. doi: 10.1002/14651858.CD000213. Cochrane Database Syst Rev. 2003. PMID: 12917889 Updated. Review. - Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta-analysis of 19 Studies.
Luo S, Zhuang M, Zeng W, Tao J. Luo S, et al. J Am Heart Assoc. 2016 May 20;5(5):e003242. doi: 10.1161/JAHA.116.003242. J Am Heart Assoc. 2016. PMID: 27207999 Free PMC article. Review.
Cited by
- Endovascular Treatment for Basilar Artery Occlusion.
Gupta D, D'Anna L, Klein P, Araujo-Contreras R, Kaliaev A, Abdalkader M, Hu W, Nguyen TN. Gupta D, et al. J Clin Med. 2024 Jul 16;13(14):4153. doi: 10.3390/jcm13144153. J Clin Med. 2024. PMID: 39064193 Free PMC article. Review. - The effect of the interaction of sleep onset latency and age on ischemic stroke severity via inflammatory chemokines.
Zhou Y, Han X, Mu Q, Xing L, Wu Y, Li C, Liu Y, Wang F. Zhou Y, et al. Front Neurol. 2024 Feb 16;15:1323878. doi: 10.3389/fneur.2024.1323878. eCollection 2024. Front Neurol. 2024. PMID: 38434201 Free PMC article. - Integrative Approaches in Acute Ischemic Stroke: From Symptom Recognition to Future Innovations.
Saceleanu VM, Toader C, Ples H, Covache-Busuioc RA, Costin HP, Bratu BG, Dumitrascu DI, Bordeianu A, Corlatescu AD, Ciurea AV. Saceleanu VM, et al. Biomedicines. 2023 Sep 23;11(10):2617. doi: 10.3390/biomedicines11102617. Biomedicines. 2023. PMID: 37892991 Free PMC article. Review. - Bayesian multilevel multivariate logistic regression for superiority decision-making under observable treatment heterogeneity.
Kavelaars X, Mulder J, Kaptein M. Kavelaars X, et al. BMC Med Res Methodol. 2023 Oct 5;23(1):220. doi: 10.1186/s12874-023-02034-z. BMC Med Res Methodol. 2023. PMID: 37798704 Free PMC article. - Admission blood pressure and clinical outcomes in patients with acute ischaemic stroke treated with intravenous alteplase and endovascular treatment versus endovascular treatment alone: A MR CLEAN-NO IV substudy.
van den Berg SA, Uniken Venema SM, LeCouffe NE, Postma AA, Lycklama À Nijeholt GJ, Rinkel LA, Treurniet KM, Kappelhof M, Bruggeman AE, van Kranendonk KR, Majoie CB, Dippel DW, van der Worp HB, Coutinho JM, Nederkoorn PJ, Roos YB. van den Berg SA, et al. Eur Stroke J. 2023 Sep;8(3):647-654. doi: 10.1177/23969873231173274. Epub 2023 May 11. Eur Stroke J. 2023. PMID: 37641554 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical